Trends in the use of highly active antiretroviral therapy in Western Denmark 1996-2000

Scandinavian Journal of Infectious Diseases

Volumn 34, Issue 6, 2002, Pages 460-465

  Jensen Fangel, Sören ^a   Pedersen, Court ^a   Larsen, Carsten S ^a   Tauris, Palle ^a   Møller, Axel ^a   Obel, Niels ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DRUG UTILIZATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; SIDE EFFECT; TREATMENT FAILURE; STATISTICS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DENMARK; HIV INFECTIONS; HUMAN; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0035990577     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540110080458     Document Type: Article

References (23)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-I infection in adults
4. The Danish protease inhibitor study. A randomized study comparing the virological efficacy of three protease-inhibitor containing regimens for the treatment of human immunodeficiency virus type 1 infection
5. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral thearapy
6. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel
7. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre
8. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
9. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
10. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug outcome
11. Changing demographics in an HIV-infected population: Results from an observational cohort study in Western Denmark
12. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: The Scan Study
13. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
14. Saquinavir hard gel suppresses viral load insufficiently in hiv-infected patients naive to anti-retroviral therapy: A retrospective cohort study
15. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir
16. The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1 infected patients: A prospective, open-label, controlled, randomized study
17. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants
18. Phenotypic cross-resistance to nelfinavir: The role of prior antiretroviral therapy and the number of mutations in the protease gene
19. Clinical efficacy of mono-therapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial
20. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
21. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: Consistent results from a observational cohort
22. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
23. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine